Biology subjects

Lozano, G.

Publications and source records attributed to Lozano, G..

2 recordsLinked to original sources

bioRxiv2026

Multi-omics analysis identifies intrinsic Trp53 driven metastatic breast cancer subtypes.

Metastatic breast cancer (mBC) is deadly, and its molecular drivers are largely unknown. Treatment is limited to systemic cytotoxic chemotherapies and tumors often become refractory. The most frequently mutated gene in MBC is TP53. The TP53R248W hotspot missense mutation is associated with poor prognosis. We generated a somatic mouse model of mammary epithelial specific Trp53R245Wexpression. Primary tumors were highly metastatic, reflecting the human molecular subtypes luminal A, luminal B, HER2, and TNBC. Transcriptomic profiling revealed three intrinsic subtypes: stem-cell like (SCL), well-differentiated metabolically active (WDMA), and immunosuppressed (IS). SCL tumors activate ribosome biosynthesis and E2F signaling, amplifying Met, Birc3, Yap1 and deleting Nf1, Pik3r1, and Rad17. WDMA tumors activate cytochrome P450 enzymes, estrogen signaling and branched chain amino acid degradation, with mutations activating Pi3k/Akt/mTOR signaling. IS tumors activate immune suppression, have high mutation burden, and frequently mutate Traf7 and delete Cdkn2a. This is the most comprehensive transcriptomic and genomic profiling of mutant p53-driven breast tumors, elucidating potential therapeutic targets. TeaserA single Trp53 mutation drives intrinsic metastatic breast cancer subtypes with distinct transcriptomes and genomic alterations.

cancer biology↗

bioRxiv2024

Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer

Mutational activation of KRAS occurs commonly in lung carcinogenesis and, with the recent FDA approval of covalent inhibitors of KRASG12C such as sotorasib or adagrasib, KRAS oncoproteins are important pharmacological targets in non-small cell lung cancer (NSCLC). However, not all KRASG12C-driven NSCLCs respond to these inhibitors, and the emergence of drug resistance in those patients that do respond can be rapid and pleiotropic. Hence, based on a backbone of covalent inhibition of KRASG12C, efforts are underway to develop effective combination therapies. Here we report that inhibition of KRASG12C signaling increases autophagy in KRASG12C expressing lung cancer cells. Moreover, the combination of DCC-3116, a selective ULK1/2 inhibitor, plus sotorasib displays cooperative/synergistic suppression of human KRASG12C-driven lung cancer cell proliferation in vitro and superior tumor control in vivo. Additionally, in genetically engineered mouse models of KRASG12C-driven NSCLC, inhibition of either KRASG12C or ULK1/2 decreases tumor burden and increases mouse survival. Consequently, these data suggest that ULK1/2-mediated autophagy is a pharmacologically actionable cytoprotective stress response to inhibition of KRASG12C in lung cancer.

cancer biology↗